graph Evidence gap map comparisons
durvalumab based treatmentnivolumab based treatmentpembrolizumab based treatment
durvalumab alone nivolumab alone pembrolizumab alone pembrolizumab plus 5FU plus platin
mHNSCC - (neo)adjuvant (NA)
mHNSCC - 1st line (L1)
mHNSCC - L1 - all population 2     
mHNSCC - L1 - PDL1 positive 4       
mHNSCC - 2nd line (L2)
mHNSCC - L2 - all population 4       
mHNSCC - L2 - PDL1 negative 2
mHNSCC - L2 - PDL1 positive 1   
Comparator:  vs cetuximab plus platin plus 5FU;   vs Standard of Care (SoC); 
Risk of bias:  low;   some concerns;   high;  NA;